Physicians remain vital in obesity care, but they are not the full picture. NPs and PAs are increasingly central to how ...
Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...
Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are ...
Texas Attorney General Ken Paxton filed a motion to prevent Kenvue from paying out its November dividend. 1 According to ...
Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...
Novo Nordisk’s amended proposal values Metsera at $86.20-per-share, for a total value upwards of $10 billion, representing an ...
Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI ...
In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...
UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback